Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
BUSINESS
Novartis Rolls Out Luxturna in Japan, 2 Treatment Facilities Selected
Novartis Pharma on August 30 launched its gene therapy Luxturna (voretigene neparvovec) for inherited retinal disease in Japan. The treatment will be available at two facilities designated by an academic society. The product is indicated for the treatment of inherited…
To read the full story
Related Article
- Japan Society to Select Facilities to Use Luxturna; 10 Sites for Genetic Testing, 2 or 3 for Treatment
August 25, 2023
- Ultra-High Cost of Luxturna Would Be Offset by Its Clinical Significance, Have Limited Financial Impact: Expert
August 25, 2023
- Luxturna Priced at 49.6 Million Yen per Vial, Peak Sales Put at 500 Million Yen with 5 Patients
August 24, 2023
- Drug Pricing Rules to Be Applied to Novartis’ Gene Therapy Luxturna
July 6, 2023
- Japan Approves Novartis’ Gene Therapy Luxturna for Rare Eye Disease
June 27, 2023
- Japan Approves 1st Gene Panel Testing for IRD
June 6, 2023
- Gene Therapy Luxturna Now in Line for Approval in June
May 29, 2023
BUSINESS
- Mochida Lifts G-Lasta Biosimilar Shipment Curbs after Over 2 Years
November 4, 2026
- Espha Taps Korean Eylea Follow-On for First Biosimilar Foray
November 4, 2026
- Kyowa Kirin Won’t Stop Drug Launches over MFN Pricing: CEO
November 4, 2026
- Takara Bio, S-RACMO Finalize Cell Processing CDMO Transfer for January
November 4, 2026
- Roche Launches CDx for Takeda’s Elahere in Japan
November 4, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…